Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519345 | 1.00 | AR (0.52) | ARALOX15NPC1CDK2RAB9A | |
| SCHEMBL22372145 | 0.83 | AR (0.57) | ARALOX15NPC1CDK2RAB9A | |
| SCHEMBL5527710 | 0.81 | NPC1L1 (0.47) | NPC1RAB9ASMN1; SMN2TEAD1TEAD3 | |
| SCHEMBL5527711 | 0.81 | NPC1L1 (0.47) | NPC1RAB9ASMN1; SMN2TEAD1TEAD3 | |
| SCHEMBL5527889 | 0.78 | KMT2A (0.45) | — | |
| SCHEMBL5527884 | 0.78 | KMT2A (0.45) | — | |
| SCHEMBL5525148 | 0.78 | HIF1A (0.44) | TEAD1TEAD3 | |
| SCHEMBL5523261 | 0.78 | HIF1A (0.44) | TEAD1TEAD3 | |
| SCHEMBL5525155 | 0.78 | HIF1A (0.44) | TEAD1TEAD3 | |
| SCHEMBL5523265 | 0.78 | HIF1A (0.44) | TEAD1TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | AR 1299/4885ALOX15 2819/4885NPC1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.